Bio-Techne バランスシートの健全性
財務の健全性 基準チェック /66
Bio-Techneの総株主資本は$2.1B 、総負債は$300.0Mで、負債比率は14%となります。総資産と総負債はそれぞれ$2.7Bと$597.4Mです。 Bio-Techneの EBIT は$243.8Mで、利息カバレッジ比率25.2です。現金および短期投資は$187.5Mです。
主要情報
14.0%
負債資本比率
US$300.00m
負債
| インタレスト・カバレッジ・レシオ | 25.2x |
| 現金 | US$187.54m |
| エクイティ | US$2.14b |
| 負債合計 | US$597.37m |
| 総資産 | US$2.74b |
財務の健全性に関する最新情報
Is Bio-Techne (NASDAQ:TECH) A Risky Investment?
Sep 26
These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well
Apr 30We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt
Jan 17Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Sep 22Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Jun 22Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Mar 21Recent updates
There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings
Nov 06Is Bio-Techne (NASDAQ:TECH) A Risky Investment?
Sep 26Why Bio-Techne Corporation (NASDAQ:TECH) Could Be Worth Watching
Sep 11Bio-Techne Corporation's (NASDAQ:TECH) Price In Tune With Earnings
Aug 24When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Jun 09Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up
May 21These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well
Apr 30Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate
Apr 15Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence
Apr 04We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt
Jan 17Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected
Dec 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Dec 05Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?
Oct 10Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Sep 22A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Sep 01At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Jul 10Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Jun 22With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case
Jun 07Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price
May 23When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Apr 05Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Mar 21Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching
Mar 06When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Jan 03We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease
Dec 15Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?
Nov 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Nov 17Bio-Techne releases new AVV viral titer assays
Oct 11At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Sep 26Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Sep 12Bio-Techne to seek shareholder approval for 4- for-1 stock split
Sep 01Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?
Aug 29財務状況分析
短期負債: TECHの 短期資産 ( $648.6M ) が 短期負債 ( $142.1M ) を超えています。
長期負債: TECHの短期資産 ( $648.6M ) が 長期負債 ( $455.2M ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: TECHの 純負債対資本比率 ( 5.3% ) は 満足できる 水準であると考えられます。
負債の削減: TECHの負債対資本比率は、過去 5 年間で42.5%から14%に減少しました。
債務返済能力: TECHの負債は 営業キャッシュフロー によって 十分にカバー されています ( 101.2% )。
インタレストカバレッジ: TECHの負債に対する 利息支払い は EBIT ( 25.2 x coverage) によって 十分にカバーされています。